Immediate Impact
2 from Science/Nature 60 standout
Citing Papers
Pancreatic cancer
2025 Standout
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment
2025 Standout
Works of Nicholas Zdenkowski being referenced
Abstract LBO1-03: Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N)
2024
Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Nicholas Zdenkowski | 286 | 163 | 108 | 189 | 56 | 569 | |
| Rebeca Franco | 237 | 114 | 84 | 101 | 39 | 560 | |
| Peter Paul Yu | 186 | 88 | 126 | 132 | 42 | 572 | |
| Albert J. Farias | 249 | 130 | 81 | 86 | 56 | 605 | |
| Ian Collins | 231 | 65 | 53 | 164 | 63 | 604 | |
| Anna Moseley | 278 | 71 | 51 | 191 | 31 | 587 | |
| Bobby Daly | 290 | 53 | 129 | 108 | 29 | 520 | |
| Brionna Y. Hair | 255 | 74 | 129 | 85 | 25 | 483 | |
| Cecilia R. DeGraffinreid | 286 | 165 | 42 | 176 | 34 | 623 | |
| Lillie D. Shockney | 408 | 92 | 66 | 152 | 26 | 541 | |
| Sue Anne McLachlan | 261 | 67 | 43 | 128 | 26 | 557 |
All Works
Login with ORCID to disown or claim papers
Loading papers...